null

Tomaralimab Biosimilar (Anti-TLR2) Antibody (HDBS0140)

SKU:
HDBS0140
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
Protein:
TLR2
Reactivity:
Human
Host Species:
Chimeric Humanized
Isotype:
IgG4
€399

Description

system_update_altDatasheet

Tomaralimab (Anti-TLR2) Biosimilar Antibody (HDBS0140)

The Tomaralimab Biosimilar Anti-TLR2 Antibody is a cutting-edge product designed for researchers studying Toll-like receptor 2 (TLR2) signaling pathways in the immune system. This antibody, produced using advanced biosimilar technology, effectively targets TLR2, a key receptor involved in the recognition of pathogen-associated molecular patterns.With its high specificity and sensitivity, the Tomaralimab Biosimilar Anti-TLR2 Antibody is an invaluable tool for investigating TLR2-mediated immune responses in various cell types and tissue samples. Its application in techniques such as Western blotting and immunohistochemistry enables precise detection and analysis of TLR2 expression and activity, facilitating a deeper understanding of immune system function and dysregulation.

TLR2 signaling plays a crucial role in the immune response to infections, inflammation, and autoimmune diseases, making the Tomaralimab Biosimilar Anti-TLR2 Antibody an essential resource for researchers exploring the immunological mechanisms underlying these conditions. By elucidating the complex interactions between TLR2 and its ligands, this antibody supports the development of novel therapeutic strategies targeting TLR2-mediated pathways for the treatment of infectious and inflammatory diseases.